1763 Stock Overview
Engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
China Isotope & Radiation Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.30 |
| 52 Week High | HK$13.72 |
| 52 Week Low | HK$9.03 |
| Beta | 0.70 |
| 1 Month Change | -3.20% |
| 3 Month Change | -5.50% |
| 1 Year Change | -12.71% |
| 3 Year Change | -61.06% |
| 5 Year Change | -56.26% |
| Change since IPO | -48.76% |
Recent News & Updates
Recent updates
China Isotope & Radiation Corporation's (HKG:1763) 36% Share Price Surge Not Quite Adding Up
Oct 07
China Isotope & Radiation's (HKG:1763) Anemic Earnings Might Be Worse Than You Think
May 05Why We're Not Concerned About China Isotope & Radiation Corporation's (HKG:1763) Share Price
Apr 26China Isotope & Radiation (HKG:1763) Has A Rock Solid Balance Sheet
Mar 28There Are Reasons To Feel Uneasy About China Isotope & Radiation's (HKG:1763) Returns On Capital
May 13Is Now The Time To Look At Buying China Isotope & Radiation Corporation (HKG:1763)?
Feb 07China Isotope & Radiation (HKG:1763) Will Want To Turn Around Its Return Trends
Dec 20A Look At The Intrinsic Value Of China Isotope & Radiation Corporation (HKG:1763)
Oct 28China Isotope & Radiation (HKG:1763) Seems To Use Debt Quite Sensibly
Sep 30There Are Reasons To Feel Uneasy About China Isotope & Radiation's (HKG:1763) Returns On Capital
Aug 30Is There Now An Opportunity In China Isotope & Radiation Corporation (HKG:1763)?
Jun 10China Isotope & Radiation (HKG:1763) Could Easily Take On More Debt
Apr 11Is It Time To Consider Buying China Isotope & Radiation Corporation (HKG:1763)?
Dec 28China Isotope & Radiation (HKG:1763) Seems To Use Debt Quite Sensibly
Oct 26Capital Allocation Trends At China Isotope & Radiation (HKG:1763) Aren't Ideal
Oct 08Is Now An Opportune Moment To Examine China Isotope & Radiation Corporation (HKG:1763)?
Sep 05Returns On Capital At China Isotope & Radiation (HKG:1763) Paint A Concerning Picture
Jun 13When Should You Buy China Isotope & Radiation Corporation (HKG:1763)?
May 24China Isotope & Radiation (HKG:1763) Has A Pretty Healthy Balance Sheet
Apr 01Our Take On The Returns On Capital At China Isotope & Radiation (HKG:1763)
Mar 14The China Isotope & Radiation (HKG:1763) Share Price Has Gained 24% And Shareholders Are Hoping For More
Feb 04
Shareholder Returns
| 1763 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -0.6% | 1.7% | 2.1% |
| 1Y | -12.7% | -18.5% | 23.7% |
Return vs Industry: 1763 exceeded the Hong Kong Medical Equipment industry which returned -18.5% over the past year.
Return vs Market: 1763 underperformed the Hong Kong Market which returned 23.7% over the past year.
Price Volatility
| 1763 volatility | |
|---|---|
| 1763 Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.0% |
| 10% least volatile stocks in HK Market | 3.1% |
Stable Share Price: 1763 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1763's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 3,132 | Junqi Zhang | www.circ.com.cn |
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; urea breath test kits and analyzers; and in vitro immunoassay diagnostic reagents and kits.
China Isotope & Radiation Corporation Fundamentals Summary
| 1763 fundamental statistics | |
|---|---|
| Market cap | HK$3.29b |
| Earnings (TTM) | HK$425.18m |
| Revenue (TTM) | HK$7.13b |
7.7x
P/E Ratio0.5x
P/S RatioIs 1763 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1763 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.71b |
| Cost of Revenue | CN¥3.24b |
| Gross Profit | CN¥3.46b |
| Other Expenses | CN¥3.06b |
| Earnings | CN¥400.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 51.61% |
| Net Profit Margin | 5.97% |
| Debt/Equity Ratio | 27.4% |
How did 1763 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 21:16 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
China Isotope & Radiation Corporation is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yanyin Zhu | China International Capital Corporation Limited |
| null null | CLSA |
| Bo Li | CLSA |